Dr. Colin Minchom has been appointed as vice president of Hovione’s particle design business unit. He will be based in East Windsor, N.J., and report to Guy Villax, CEO of Hovione.

Minchom brings 29 years of experience in the process, science and global regulation of drug development, with emphasis on dosage forms and drug delivery. Previously, he has served at Patheon as vice president, pharmaceutical development services for North America. Minchom has also held positions at Eli Lilly, Cerebrus, a private U.K. pharmaceutical company, and ER.

He is also chair of the American Association of Pharmaceutical Scientists (AAPS) 2012 Annual Meeting Planning Committee for Chicago and volunteers at the United States Pharmacopoeia (USP) as member of an Expert Committee addressing small molecules.